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Living in San Diego as I do, I often encounter patients who
cross into Mexico to buy their prescription drugs. This
practice, which is perhaps even more common in states that
border Canada, has culminated in legislation passed by the
House of Representatives (H.R. 2427, generally referred to
as the “Prescription Drug Reimportation Bill”) that would
potentially allow drug wholesalers and pharmacists to reim-
port drugs from a number of industrialized countries. This
legislation, which is currently tied up in considerations
surrounding a Medicare reform package and prescription-
drug bill, has generated strong feelings among consumers,
elected officials, and the pharmaceutical industry. Despite the
strong opinions expressed both for and against drug reimpor-
tation, the issue is complex, the factual data incomplete, and
the consequences unpredictable. As physicians, we sit squarely
in the middle of this debate, wanting both affordable medi-
cations for our patients as well as continued support for the
development of innovative pharmacologic therapies.
The problem that the drug reimportation bill was de-
signed to address directly is easily documented. Drugs
constitute approximately 10% of the expenditures of the
Center for Medicare and Medicaid Services (CMS), for-
merly the Health Care Financing Administration (HCFA).
According to the Consumers Union (1), drug costs have
been increasing by 15% to 20% per year, about twice the
Consumer Price Index, and are projected to reach $243
billion by 2008. Based on surveys, the majority of individ-
uals 65 years and older expend 10% of their income on
health care costs, largely for prescription drugs. Of concern,
17% of all Americans and 42% of uninsured Americans
report that they have failed to fill prescriptions for financial
reasons. As drug prices continue to rise, these problems can
be expected to increase.
While the escalating costs of prescribed pharmaceuticals
in the U.S. is problem enough by itself, it is magnified by
the fact that the prices paid by citizens of other industrial-
ized countries are less. Hard data on the cost differences
between the U.S. and other countries are lacking, but these
differences have been estimated to be as high as 35% for
non-generic drugs. A recent survey conducted by the Asso-
ciated Press found that 10 of the most-prescribed drugs
were 33% to 80% cheaper in Canada than in the U.S. (2).
Lipitor, for instance, was 37% cheaper in Canada. The
reduced cost of pharmaceuticals in other countries is attrib-
utable to price controls, a concept that is antithetical to our
capitalist system. Given these price controls, pharmaceutical
companies derive minimal profits overseas and must recoup
their development expenses and generate their profits from
the U.S. Although the American people have considerable
compassion and generosity, and are willing to subsidize
medications for developing countries, it does not seem
reasonable that citizens of industrialized countries with a
standard of living comparable to our own should receive
subsidies.
The proposed solution to the foregoing problems was the
prescription drug reimportation bill introduced by Repre-
sentative Gil Gutknecht of Minnesota. This bill would
extend the right to reimport drugs from pharmaceutical
companies to wholesalers and pharmacists. The legislation
restricts the countries from which drugs could be imported
and stipulates that reimportation be contingent upon the
Food and Drug Administration’s (FDA) ability to ensure
the safety of the process and upon the provision of proof of
cost savings—efforts for which funding was not provided.
The bill estimated that Americans could save hundreds of
billions of dollars per year—a figure that is debated.
It is not surprising that opponents of reimportation
rapidly delineated its limitations. The most obvious issue
deals with safety, and the FDA commissioner himself
indicated that his agency could not guarantee the safety,
purity, and efficacy of imported drugs. No safety issues have
been encountered thus far with the current level of impor-
tation, but the scale of importation anticipated by the
legislation would make products susceptible to major mod-
ification. The actual savings that would accrue were called
into question, particularly with regard to generics and to the
add-on costs entailed in administering the process and
retailing the drugs. From a conceptual standpoint, many
objected to the fact that reimportation would, in essence,
subject the U.S. to the price controls and pharmaceutical
policies of a foreign government. However, of perhaps
greatest consequence, reduced U.S. profits for prescribed
drugs could eliminate the funds necessary to support the
expensive drug discovery and development effort of the
pharmaceutical industry. Clearly, we in cardiology have
benefited as much as anyone from the continuous stream of
effective new agents flowing from the pharmaceutical pipe-
line as a result of heavy investment in research and devel-
opment (R and D). Any threat to this process could have a
major negative impact on the health of society.
Two issues loom in the background of the debate regard-
ing reimportation, and they act to color all the interchange.
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The first is the profitability of the pharmaceutical industry.
The pharmaceutical industry has been the most profitable
business in the American economy for the past 10 years.
Although drug companies are among the leaders in spend-
ing on R and D, they also devote substantial dollars to
marketing and advertising, of which direct-to-consumer
media advertising is a prime example. In their own defense,
pharmaceutical executives point out that it currently costs
approximately $800 million to bring a drug to market and
that only 3 of 10 new drugs ever return the investment in
development. Nevertheless, the escalating costs of drugs
combined with the robust profits of pharmaceutical compa-
nies create the impression that drug prices could be reduced
without a detrimental effect on the industry. The second
issue is the general concept of price controls. Majority
opinion favors free market control as the optimal method of
determining the value of goods and services. Even most
advocates of drug reimportation foresee it as a method of
equalizing prices in the industrial world rather than as price
controls. Thus, in a sense, reimportation serves as a surro-
gate issue for questions regarding the very nature of our
capitalist system.
Much of the disagreement over drug reimportation re-
lates to uncertainty concerning what consequences will
follow. Under one pessimistic scenario, industry profits will
plummet, R and D will cease, and no new drugs will be
introduced. A proportionately optimistic view is that com-
panies will no longer sell to other countries at low prices,
foreign governments will be forced to drop price controls to
provide their citizens life-saving pharmaceuticals, and in-
equities in drug prices will be eliminated throughout the
industrialized world. Your position on this issue depends on
which of these scenarios you think will occur. The problem
is, of course, that no one can predict with certainty.
Where does all this leave cardiologists? Clearly, we have
vested interests on both sides of the issue. It is of paramount
importance that prescription drugs be readily affordable to
our patients. Any action that we can take to achieve this goal
is mandatory. The solution should also address the inequi-
ties of current international drug prices. Similarly, we must
ensure that our productive pharmaceutical industry has
sufficient financial support to continue to bring new thera-
peutic agents to market. It would be catastrophic to kill the
goose that laid the golden egg. So we sit in the middle.
Personally, I believe that reimportation is a distraction from
the major problem, which is the need to provide proven
drugs to every patient who requires them. If the only way to
accomplish this within existing resources is to negotiate
price reductions, then the government should take this on
directly, not through reimportation. However, even with
substantial price reductions, through negotiations or reim-
portation, some patients will still be unable to afford drugs.
Therefore, I believe the only sure solution is a prescription-
drug benefit that provides all patients with the drugs we
determine they need. We may be in the middle on reim-
portation, but there should be no doubts about the desir-
ability of a reasonable, nonintrusive prescription drug ben-
efit package.
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